Uncovering the Benefits of State Wide Prescription Drug Affordability Board’s to Reduce High Costs Associated with GLP-1s for Diabetes
Time: 12:30 pm
day: Conference Day One
Details:
- Detailing the specific powers and mandate of the Maryland Prescription Drug Affordability Board (PDAB), highlighting their recent or ongoing focus on the cost of GLP-1 receptor agonists, given their significant utilization and budget impact
- Explaining the processes, the Maryland PDAB employs to review the cost of GLP-1s, including data analysis, stakeholder engagement, and the potential mechanisms they might utilize to recommend or set upper payment limits or negotiate supplemental rebates
- Discussing the anticipated effects of the Maryland PDAB’s actions on GLP-1 pricing for patients, payers (including the state Medicaid program), healthcare providers, and pharmaceutical manufacturers, and consider the potential for Maryland’s approach to influence other states or federal policies
